होम
एक्सप्लोर
nav.journalClub
ट्रेंडिंग
और
synapse
⌘+K
भाषा
हिन्दी
हिन्दी
Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov | Synapse
March 3, 2026
Open Access
Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov
SP
Shruti Patil
The University of Texas Southwestern Medical Center
NJ
Nandini Jha
The University of Texas Southwestern Medical Center
MJ
Manish K. Jha
The University of Texas Southwestern Medical Center
Key Points
GLP-1 receptor agonists may impact treatment outcomes for substance use disorders, enhancing recovery processes.
The analysis reveals significant data from clinical trials focusing on behavioral and pharmacological interventions.
Systematic review across multiple studies demonstrates the potential benefits of using GLP-1 receptor agonists.
Research highlights a growing interest in the application of GLP-1 receptor modulation in addiction treatment.
Read Full Paper
externally
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
Cite This Study
Copy
Patil et al. (Fri,) studied this question.
synapsesocial.com/papers/69a75f47c6e9836116a2a89d
https://doi.org/https://doi.org/10.1016/j.abrep.2026.100671